Your browser is old and is not supported. Upgrade for better security.
Wefunder logo

Sen-Jam Pharmaceutical

Revolutionizing Pain Management with Existing Therapeutics for a $17B Market

Last Funded August 2022


raised from 384 investors
Pitch Video
Investor Panel


Highly effective existing drugs repurposed for: COVID-19, opioid withdrawal & hangover prevention
Secured lead strategic partner for Global Distribution
$17B Addressable market opportunity in US alone
Current valuation (rNPV): COVID-19: $55M, hangover prevention: $120M, and opioid withdrawal" $261M
Oral COVID-19 therapy clinical trial currently underway with Duke-NUS for valuation inflection point
Female founder is innovative clinical pharmacist and thought leader
Team is mission-oriented, with like-minded focused on worldwide healthcare and proven track record
Global IP includes 25 patents and patents pending

Our Team

We are on a mission to revolutionize not just the way we treat pain, but the way the business of pain relief treats humanity. We love the idea: Pharma for the People. Our products treat at the source; preventing symptoms vs. masking them as most therapies do today. And our products are safe & highly affordable. And that's just good for all of us.

Revolutionizing Pain Management and Big Pharma So Humanity Can Thrive

Quick Investment Summary

We are on a mission to improve societal well-being by repurposing proven therapeutics to develop new therapeutics that are safe, efficacious, and accessible by all. Why? Because we actually want to solve the world’s largest unmet healthcare needs and improve lives! Not very Big Pharma of us.

Sen-Jam is pursuing products to disrupt pain and inflammation. Our 3 lead products will treat the much-needed healthcare needs of:

  • COVID-19 Symptoms
  • Opioid Withdrawals
  • Alcohol Hangover Prevention

Using our patented proprietary technology and the accelerated 505(b)2 regulatory pathway, we will revolutionize the way we treat pain and the way the business of pain relief treats humanity. Join us as we strive to give everyone a chance at Full Strength Living!

Our mission truly is to help humanity thrive and ensure the business of inflammation treats people fairly and fully.  The time is now to upend this environment and restore dignity to the way pharma delivers solutions for the people, to the people.


Inflammation is the key to countless ailments that have a tremendous impact on billions of people globally. As a registered pharmacist, our co-founder, Jacqueline Iversen spent decades of observing the debilitating pain from inflammation in her patients. She knew there was a better way to treat a wide range of conditions including arthritis, seasonal colds and flu, and COVID-19.

A safe and effective anti-inflammatory would make a massive difference for the health concerns of so many. With recent pandemics (COVID-19), epidemics (opioids), and consistent behaviors (alcohol use), the need is even more urgent.


Sen-Jam Pharmaceutical is addressing that need by formulating a platform of therapeutics targeting pain and inflammation. And we found the solution already existed in safe, tested, over-the-counter drugs that weren’t being used to address pain.

Our studies have shown that combining NSAIDS with Antihistamines has a dramatic disruptive action in the inflammatory conditions leading to acute or chronic pain. By repurposing these 2 small molecules, this simple combination product will have a massive, positive impact on major health conditions.

In addition, our products will help avoid the problems before they need treatment. So, we’re not chasing the problem, we’re preventing it!

Our three lead products -- COVID-19, Opioid Withdrawal and Alcohol Hangover -- have enormous and distinct benefits for each of their therapeutic areas. All are oral, safe, effective, affordable, and accessible to people worldwide.

Total Addressable Market for our First 3 Products

The annual market size of our 3 lead products is $17B per year. And that’s just the beginning of our 8-product pipeline.

Significant Pipeline Benefits

Our lead products are remarkably robust and we have 5 other products that would be added to the flock in the near future.

Praises from Thought Leaders

Here are some of the comments we've received around our solutions.

COVID-19 Therapeutic (SJP-002C)

Coronaviruses, including COVID-19, are with us for the long haul and excessive inflammation is a hallmark of severe COVID-19. Introducing a simple and cost effective therapeutic to the mix of currently available treatments, will help lessen the impact of this virus worldwide.

SJP-002C will provide antiviral activity and broad spectrum anti-inflammatory capabilities, while also reducing fever and cough. This will help to prevent mild COVID from spiraling into a cytokine storm and progressing to hospitalization or death.

Scientists and clinical researchers at Duke University Medical School in Singapore were so impressed with our product that they partnered with us on our clinical trial in Katmandu, Nepal. Why Nepal? Because the competition for unvaccinated patients in the U.S. for the trial is far too intense.

While there’s a lot of competition to get to an Oral COVID-19 therapeutic, none of the existing options or players hustling for solutions have the simplicity, accessibility, and affordability of our product.

Opioid Withdrawal Therapeutic (SJP-005)

The opioid crisis is another huge unmet need that is harrowing our society with a escalating negative social (and economic) impact each year. The number one reason people remain dependent on opioids is the excruciating effects on their bodies when they attempt withdrawal. They are in pain.

SJP-005 will reduce the painful and inflammatory effects of withdrawal, helping people ween off these dangerous opioids effectively. Our product could help MILLIONS in their fight against this crisis.

Alcohol Hangover Prevention Therapeutic (SJP-001)

There are an estimated 3B alcohol hangovers each year in the U.S., and hangovers cost society $180B annually in lost productivity.

SJP-001, when taken before drinking, reduces the inflammation and subsequent pain commonly referred to as hangover. People will wake up feeling refreshed and productive. SJP-001 will be the first FDA approved OTC product for the prevention of alcohol hangover.

Competition for the alcohol hangover market is modest at best with most assuming you simply have to suffer the consequences in silence. We beg to differ. Our product FAR outperforms the existing solutions and the market for this product is significant.

Our Team

Our team reflects a strong, nimble collective of highly experienced scientists, entrepreneurs and regulatory go-getters who are passionate about doing things resourcefully and effectively. We have deep roots in traditional pharma and as such have the drive to revolutionize the way the business brings solutions to the people. We also have deep roots in building successful businesses with over $80M in exits between us!

Our talented team cares deeply about ensuring our very real solutions make massively positive impacts on the world at reasonable costs. We’ve seen the bad with our careers and we’re creating the better with Sen-Jam.

Strong IP

Our IP is incredibly strong and gaining momentum every day with 25 patents and patents pending. Not just here in the U.S., but also abroad in important marketplaces that also need our solutions.

Forward-looking projections cannot be guaranteed.

Path to Market

Yes, drug development can be a long road, but our combination product repurposes two existing small molecules, putting us on the accelerated 505(b)(2) regulatory pathway.

Our goal is to sell or license each product by 2025. With a proven process and an experienced team adhered to systematic precision, we are positioned to do just that.

Forward-looking projections cannot be guaranteed.

Our Business Model

Here are the key inflection points for each of our 3 lead assets and the timing across the milestones to achieve prime value accordingly.

Forward-looking projections cannot be guaranteed.

Revenue forecasts are base assumptions and illustrate the lucrative nature of these therapeutic areas and unmet needs. Our business model is to sell or license our assets to a commercial partner as we advance through the regulatory process. 

Forward-looking projections cannot be guaranteed.

The Ask

We are raising $5M in funding and have already raised $2.6M from an incredible investor community. We’re now looking to raise the remaining funds to get us to our $5M goal and expedite our path-to-market activities.

Our 2022 goals and milestones following this raise are:

  • Advance our 3 lead products through FDA regulatory process until they are sold or licensed
  • Secure further IP for future pipeline
Forward-looking projections cannot be guaranteed.
The Wefunder Campaign accounts for 1.07 million of this raise

We hope you’ll join us on our mission to bring Full Strength Living to the world by providing cost-effective inflammation therapeutics to people throughout the world. It’s time to upend the existing pharma environment and restore dignity to the way pharma solutions are delivered for the people, to the people.